{
    "nctId": "NCT01232062",
    "briefTitle": "Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients",
    "officialTitle": "Study of High-dose Chemotherapy Combined With Adoptive Cellular Therapy With Dentritic and Cytokine-induced Killer Cells in Triple Negative Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Neoplasm Metastasis",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "response to chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Failure to anthracycline and/or taxol chemotherapy;\n* metastatic tumor is histologically confirmed by immunohistochemical staining to be ER-negative and PR-negative. FISH testing for her-2-negative;\n* Metastatic tumor can not be removed through surgery procedure;\n* Metastatic tumor measured by PET-CT scan is at least 1cm;\n* An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* Normal cardiac, hepatic, renal and bone marrow functions;\n* Life expectancy \u22653 months.\n\nExclusion Criteria:\n\n* Do not finish twice PET-CT scan;\n* Central nervous system metastases;\n* Serious or uncontrolled concurrent medical illness;\n* History of other malignancies;\n* Having been enrolled in some other clinal trials within a month;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}